Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol
Background Current antiretroviral regimens have, for the most part, achieved optimal antiretroviral efficacy and tolerability, transforming HIV infection from a deadly disease into a manageable chronic condition. However, adherence to daily oral drug intake remains an issue, as it is the most import...
Saved in:
| Main Authors: | Xiaodi Li, Hai Yu, Wei Cao, Xiaosheng Liu, Taisheng Li, Yuan-ni Wu, Lianfeng Lu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/12/e063089.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans
by: Rosie Mngqibisa, et al.
Published: (2025-07-01) -
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
by: Valentina Iannone, et al.
Published: (2025-01-01) -
Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland
by: Andrzej Załęski, et al.
Published: (2025-02-01) -
Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study
by: Diana Hernández-Sánchez, et al.
Published: (2025-07-01) -
Attitudes and eligibility of long-acting cabotegravir/rilpivirine treatment among youth living with HIV in a clinical and national cohort in Thailand: a cross-sectional study
by: Punnathorn Auaboonkanok, et al.
Published: (2025-07-01)